We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$127B
1-Year Est. Return
46.06%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+46.06%
3 Year Est. Return
+142.12%
5 Year Est. Return
+190.33%
10 Year Est. Return
+787.47%
AUM
$51.2B
AUM Growth
+$4.14B
(+8.8%)
Cap. Flow
+$2.35B
Cap. Flow
% of AUM
4.58%
Top 10 Holdings %
Top 10 Hldgs %
19.89%
Holding
3,234
New
648
Increased
710
Reduced
838
Closed
835
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.99B |
| 2 |
Microsoft
MSFT
|
+$522M |
| 3 |
Advanced Micro Devices
AMD
|
+$511M |
| 4 |
Amazon
AMZN
|
+$318M |
| 5 |
Apple
AAPL
|
+$317M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$402M |
| 2 |
McDonald's
MCD
|
+$375M |
| 3 |
Visa
V
|
+$366M |
| 4 |
Meta Platforms (Facebook)
META
|
+$319M |
| 5 |
Adobe
ADBE
|
+$272M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.66% |
| 2 | Healthcare | 17.11% |
| 3 | Miscellaneous | 15.83% |
| 4 | Consumer Discretionary | 13.3% |
| 5 | Financials | 8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Coca-Cola
KO
$380B
| $104M | 0.2% |
1,732,424
+1,546,051
| +830% | +$96.2M |
|
102
Regeneron Pharmaceuticals
REGN
$83.4B
| $103M | 0.2% |
143,508
+52,710
| +58% | +$40.6M |
|
|
WCC
103
WESCO International
WCC
$17.6B
| $102M | 0.2% |
572,375
+256,454
| +81% | +$37.4M |
|
104
Trip.com Group
TCOM
$25.5B
| $102M | 0.2% |
2,915,664
-1,111,913
| -28% | -$38.7M |
|
105
Boston Scientific
BSX
$65.2B
| $102M | 0.2% |
1,881,267
-2,351,499
| -56% | -$123M |
|
|
SWAV
106
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $101M | 0.2% |
355,620
-273,453
| -43% | -$75.9M |
|
107
CoStar Group
CSGP
$12.3B
| $99.5M | 0.19% |
1,117,914
-499,266
| -31% | -$38.5M |
|
108
Graphic Packaging
GPK
$2.93B
| $99.4M | 0.19% |
4,136,529
+1,097,093
| +36% | +$27.5M |
|
109
Trade Desk
TTD
$6.59B
| $98.3M | 0.19% |
1,273,453
+834,324
| +190% | +$56.5M |
|
110
Ross Stores
ROST
$73.3B
| $97.6M | 0.19% |
870,597
-1,582,526
| -65% | -$166M |
|
111
Expedia Group
EXPE
$33B
| $96.1M | 0.19% |
878,679
+268,237
| +44% | +$26.3M |
|
112
Cadence Design Systems
CDNS
$78.2B
| $94.3M | 0.18% |
401,935
+348,477
| +652% | +$75.8M |
|
113
PUT
Palo Alto Networks
PANW
$275B
| $93.4M | 0.18% |
731,400
+351,000
| +92% | +$36.5M |
|
|
114
PUT
Apple
AAPL
$4.61T
| $91.8M | 0.18% |
473,400
+5,600
| +1% | +$976K |
|
|
EXAS
115
DELISTED
Exact Sciences
EXAS
| $91.6M | 0.18% |
+975,054
| New | +$76.1M |
|
116
Broadcom
AVGO
$1.75T
| $91.4M | 0.18% |
1,053,800
+499,290
| +90% | +$35.6M |
|
117
Salesforce
CRM
$205B
| $91.3M | 0.18% |
432,183
+108,404
| +33% | +$22.1M |
|
118
Kimberly-Clark
KMB
$34.2B
| $90.6M | 0.18% |
656,567
+181,045
| +38% | +$25.2M |
|
119
iShares Russell 2000 ETF
IWM
$80.1B
| $90.3M | 0.18% |
482,040
+461,355
| +2,230% | +$82.3M |
|
120
Constellation Brands
STZ
$20.7B
| $90.2M | 0.18% |
366,463
+360,951
| +6,548% | +$84.5M |
|
121
Inspire Medical Systems
INSP
$1.8B
| $89.9M | 0.18% |
276,977
+119,058
| +75% | +$34M |
|
122
Charles River Laboratories
CRL
$13.4B
| $89.7M | 0.18% |
426,526
-528,388
| -55% | -$105M |
|
123
Xenon Pharmaceuticals
XENE
$5.77B
| $89.3M | 0.17% |
2,320,419
-167
| -0% | -$6.64K |
|
124
Cisco
CSCO
$430B
| $88.8M | 0.17% |
1,716,133
+550,519
| +47% | +$27.1M |
|
125
CALL
Invesco QQQ Trust
QQQ
$490B
| $88.5M | 0.17% |
239,600
-259,800
| -52% | -$87.5M |
|
Similar funds
Marshall Wace's Q2 2023 Portfolio in Review
As of Q2 2023, Marshall Wace held 3,234 positions worth $51.2B, up 8.8% from $47.1B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Marshall Wace deployed $2.35B of net new capital in Q2 2023, opening 648 new positions and adding to 710 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 4,713,944 shares worth $2.1B.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 14% a quarter earlier, followed by Healthcare and Miscellaneous.
On the sell side, the largest reduction was Gilead Sciences, an estimated $402M trimmed.
- Marshall Wace's largest Q2 2023 buy was iShares Core S&P 500 ETF: 4,713,944 shares worth $2.1B.
- Marshall Wace added most to Microsoft in Q2 2023, an estimated $522M increase.
- Marshall Wace's biggest Q2 2023 reduction was Gilead Sciences, cutting an estimated $402M.
- Marshall Wace fully exited Cloudflare in Q2 2023, selling an estimated $136M.
- Marshall Wace's ten largest holdings make up 20% of its $51.2B portfolio in Q2 2023.
- Marshall Wace opened 648 new positions and closed 835 in Q2 2023.
- Marshall Wace's portfolio value rose 8.8% quarter-over-quarter to $51.2B.
Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.